Literature DB >> 8419168

T suppressor hybridomas and interleukin-2-dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis.

R Aharoni1, D Teitelbaum, R Arnon.   

Abstract

Suppressor T (Ts) hybridomas and interleukin-2-dependent T cell lines were established from spleens of mice, which had been rendered unresponsive to experimental allergic encephalomyelitis (EAE) either by mouse spinal cord homogenate or by the synthetic suppressant copolymer 1 (Cop 1). The Ts hybridoma supernatants and the Ts line cells specifically suppressed the in vitro response to the encephalitogenic myelin basic protein (BP), as indicated by inhibition of both the proliferation and interleukin-2-secretion responses of a BP-specific T cell line. Moreover, these Ts cells prevented the development of actively induced EAE in vivo. All hybridomas and lines were most effective when injected at the time of disease induction, thus suggesting that they operate as effector suppressor cells, and functionally inhibit encephalitogenic responses. The data presented here suggest that the suppressor cells are stimulated by the protective epitopes included in the BP as well as in the Cop 1 molecules and that they play an active role in the regulation of EAE. The generation of Ts lines and hybridomas, which have been induced by Cop 1, establish the specific stimulation of suppressor cells to EAE as a mechanism underlying the therapeutic activity of Cop 1.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8419168     DOI: 10.1002/eji.1830230105

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  22 in total

Review 1.  Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.

Authors:  H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

2.  Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1.

Authors:  R Aharoni; D Teitelbaum; O Leitner; A Meshorer; M Sela; R Arnon
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

3.  Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking.

Authors:  R Aharoni; D Teitelbaum; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

4.  Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma.

Authors:  H Schori; J Kipnis; E Yoles; E WoldeMussie; G Ruiz; L A Wheeler; M Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

5.  Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.

Authors:  P W Duda; M C Schmied; S L Cook; J I Krieger; D A Hafler
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

6.  Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1).

Authors:  R Balabanov; D Lisak; T Beaumont; R P Lisak; P Dore-Duffy
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

7.  Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms.

Authors:  Joel N H Stern; Zsolt Illés; Jayagopala Reddy; Derin B Keskin; Eric Sheu; Masha Fridkis-Hareli; Hiroyuki Nishimura; Celia F Brosnan; Laura Santambrogio; Vijay K Kuchroo; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-03       Impact factor: 11.205

8.  A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo.

Authors:  P G Schlegel; R Aharoni; Y Chen; J Chen; D Teitelbaum; R Arnon; M Sela; N J Chao
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

Review 9.  Neurogenesis and neuroprotection in the CNS--fundamental elements in the effect of Glatiramer acetate on treatment of autoimmune neurological disorders.

Authors:  Ruth Arnon; Rina Aharoni
Journal:  Mol Neurobiol       Date:  2007-10-11       Impact factor: 5.590

Review 10.  Mechanism of action of glatiramer acetate in treatment of multiple sclerosis.

Authors:  Martin S Weber; Reinhard Hohlfeld; Scott S Zamvil
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.